BGE-102
BGE-102, oral NLRP3 inflammasome inhibitor
BioAge's brain-penetrant NLRP3 inhibitor that cut the inflammation marker hsCRP by a median 86% in two weeks in Phase 1, the strongest human anti-inflammaging signal from a geroscience company so far.
Overview
NLRP3 is the inflammasome that drives IL-1beta and much of the chronic low-grade inflammation of aging. In a Phase 1 reported in April 2026, 120 mg of BGE-102 daily lowered hsCRP by a median 86% by day 14 in adults with obesity and elevated inflammation, with only mild to moderate adverse events. BioAge planned a Phase 2 in cardiovascular risk and a diabetic macular edema study in 2026. The company's previous lead, the apelin agonist azelaprag, was stopped for liver toxicity in 2024.
Mechanism of action
Small-molecule inhibition of the NLRP3 inflammasome, blocking caspase-1 activation and IL-1beta release.
Key studies & citations
- Human2026
BioAge reports positive Phase 1 data for BGE-102
Median 86% reduction in hsCRP at day 14 on 120 mg.
BioAge Labs press release - Human2026
BioAge announces indication expansion for BGE-102
Phase 2 programs in cardiovascular risk and eye disease.
BioAge Labs press release
Frequently asked questions
Is BGE-102 an anti-aging drug?
It targets a mechanism of aging (chronic inflammation), but it is being developed for specific diseases. No trial measures lifespan or healthspan directly.